Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C. http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C. http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
Where Will CRISPR Therapeutics Be in 5 Years?: https://g.foolcdn.com/editorial/images/757823/people-discussing-a-sales-report.jpg
Where Will CRISPR Therapeutics Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

Where Will CRISPR Therapeutics Be in 5 Years?: https://g.foolcdn.com/editorial/images/757823/people-discussing-a-sales-report.jpg
Where Will CRISPR Therapeutics Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

Where Will CRISPR Therapeutics Be in 5 Years?: https://g.foolcdn.com/editorial/images/757823/people-discussing-a-sales-report.jpg
Where Will CRISPR Therapeutics Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

3 Industry Stalwarts You Can Buy and Forget About: https://g.foolcdn.com/editorial/images/757811/businessman-with-a-stock-chart-in-the-background.jpg
3 Industry Stalwarts You Can Buy and Forget About

Don't have a lot of time to follow stocks and want some safe options for your portfolio? Three stocks that are big names within their respective industries and that can make for excellent long-term

3 Industry Stalwarts You Can Buy and Forget About: https://g.foolcdn.com/editorial/images/757811/businessman-with-a-stock-chart-in-the-background.jpg
3 Industry Stalwarts You Can Buy and Forget About

Don't have a lot of time to follow stocks and want some safe options for your portfolio? Three stocks that are big names within their respective industries and that can make for excellent long-term

3 No-Brainer Healthcare Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/758186/older-woman-laptop.jpg
3 No-Brainer Healthcare Stocks to Buy Right Now

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

3 No-Brainer Healthcare Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/758186/older-woman-laptop.jpg
3 No-Brainer Healthcare Stocks to Buy Right Now

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

Coachella Valley Behavioral Health Hosts Ceremony to Celebrate Grand Opening: https://mms.businesswire.com/media/20231214490244/en/1971221/5/ACHCCoachella_Valley_photo.jpg
Coachella Valley Behavioral Health Hosts Ceremony to Celebrate Grand Opening


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest acute care hospital, Coachella Valley Behavioral Health, located at 81555 JFK Court in Indio, California. A

Why Medtronic Stock Topped the Market on Thursday: https://g.foolcdn.com/editorial/images/758350/patient-and-physician-smiling-during-a-visit.jpg
Why Medtronic Stock Topped the Market on Thursday

Prominent medical-device maker Medtronic (NYSE: MDT) was a hit on the stock exchange Thursday. The company's share price rose by nearly 2% following regulatory approval of an important new product

Agilent Again Named “Global Lighthouse” by World Economic Forum for Manufacturing Innovations: https://mms.businesswire.com/media/20231214650148/en/1971044/5/30.jpg
Agilent Again Named “Global Lighthouse” by World Economic Forum for Manufacturing Innovations


Agilent Technologies Inc. (NYSE: A) today announced the company’s manufacturing facility in Waldbronn, Germany, has been named a Global Lighthouse by the World Economic Forum (WEF) for innovations

CenterWell Home Health collects 289,000 meals for needy Americans: https://mms.businesswire.com/media/20231214133178/en/1969536/5/IMG_0004_Grand_Junction.jpg
CenterWell Home Health collects 289,000 meals for needy Americans


CenterWell Home Health, one of America’s largest providers of home health, has supplied more than a quarter-million meals in its latest drive to feed people in need in the communities it serves

3 Stocks to Buy Before 2024 That Can Set You Up For Life: https://g.foolcdn.com/editorial/images/757806/a-couple-smiling-and-talking-with-an-advisor.jpg
3 Stocks to Buy Before 2024 That Can Set You Up For Life

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

3 Stocks to Buy Before 2024 That Can Set You Up For Life: https://g.foolcdn.com/editorial/images/757806/a-couple-smiling-and-talking-with-an-advisor.jpg
3 Stocks to Buy Before 2024 That Can Set You Up For Life

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

3 Stocks to Buy Before 2024 That Can Set You Up For Life: https://g.foolcdn.com/editorial/images/757806/a-couple-smiling-and-talking-with-an-advisor.jpg
3 Stocks to Buy Before 2024 That Can Set You Up For Life

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?: https://g.foolcdn.com/editorial/images/757807/a-couple-counting-money.jpg
Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?: https://g.foolcdn.com/editorial/images/757807/a-couple-counting-money.jpg
Are These 3 Cheap Dividend Stocks With High Yields Too Good to Be True?

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?: https://g.foolcdn.com/editorial/images/758152/device-investor-getty.jpg
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?: https://g.foolcdn.com/editorial/images/758152/device-investor-getty.jpg
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million